Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

Aug 30, 2014
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-new-heart-failure-medicine-lcz696-cut-cardiovascular-deaths-20-vs-ace-inhibitor-landmark-paradigm-hf-trial-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-new-heart-failure-medicine-lcz696-cut-cardiovascular-deaths-20-vs-ace-inhibitor-landmark-paradigm-hf-trial-0